再次外科二尖瓣置换较经导管瓣中瓣长期生存更优:多中心队列
本研究为多中心回顾性队列,纳入2004至2023年因二尖瓣生物瓣衰败接受再次外科二尖瓣置换(rSMVR)或经导管二尖瓣瓣中瓣(mViV)且无活动性心内膜炎的患者。
要点
- rSMVR与mViV的30天MVARC手术成功率相似,仅rSMVR延长通气更多。
核心结论
- 在经多学科心脏团队评估适合外科手术的患者中,rSMVR与更优的长期生存和血流动力学耐久性相关。
研究设计与样本
- 回顾性多中心队列研究,纳入2个四级医疗中心2004至2023年因二尖瓣生物瓣衰败且无活动性心内膜炎行mViV或rSMVR的患者共229例(rSMVR 90例,mViV 139例)。
主要发现
- 30天MVARC手术成功率两组相似,仅rSMVR延长通气更多。
临床怎么用
- 对二尖瓣生物瓣衰败患者,治疗决策应权衡短期风险与长期结局,由多学科心脏团队评估。
局限性
- 回顾性队列设计,可能存在选择偏倚,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Although transcatheter mitral valve-in-valve replacement (mViV) is safe, long-term outcomes compared with reoperative surgical mitral valve replacement (rSMVR) remains unknown. This study compared long-term outcomes between mViV and rSMVR in patients with failing mitral bioprostheses. METHODS: This retrospective, cohort study analyzed patients undergoing mViV or rSMVR for failing bioprosthetic mitral valves without active endocarditis at 2 quaternary care centers from 2004 to 2023. Primary end points included 30-day Mitral Valve Academic Research Consortium (MVARC) procedural success, 5-year cumulative incidence of death, freedom from reintervention, and cumulative incidence of heart failure. Echocardiographic evaluation of mean mitral valve gradients was assessed at baseline and 5-year follow-up. RESULTS: Of 229 patients (90 rSMVR, 139 mViV; mean age, 66.0 vs 68.7 years), MVARC 30-day outcomes were similar except for higher prolonged ventilation with rSMVR. At 5 years, rSMVR had significantly lower mortality (20.3% vs 40.9%; P = .01) and lower mean (standard deviation) mitral gradients (immediate postprocedure: 5.1 [2.3] mm Hg vs 7.8 [3.0] mm Hg; 5-year: 5.3 [2.0] mm Hg vs 9.8 [5.3] mm Hg; P < .001). Freedom from mitral valve reintervention (5.8% vs 6.1%; P = .97) and cumulative heart failure incidence (14.3% vs 22.9%; P = .17) were similar. CONCLUSIONS: Although mViV demonstrated comparable 30-day MVARC outcomes, rSMVR was associated with superior long-term survival and hemodynamic durability among patients deemed appropriate surgical candidates by a multidisciplinary heart team. Treatment decisions should balance short-term risk with long-term outcomes.
引用
- Won D, Bolling SF, Romano MA, et al. Long-Term Survival Advantage of Reoperative Surgical Mitral Valve Replacement Over Transcatheter Mitral Valve-in-Valve: A Multicenter Cohort. Ann Thorac Surg. 2026. PMID: 41995635. doi:10.1016/j.athoracsur.2026.03.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。